alpha-aminopyridine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Crapser, JD; Green, KN; Ochaba, J; Reidling, JC; Soni, N; Thompson, LM | 1 |
| Akhtar, A; Bansal, Y; Bishnoi, M; Kuhad, A; Sah, SP; Saroj, P; Singh, R; Sodhi, RK | 1 |
| Fehling, C; Lundh, H | 1 |
3 other study(ies) available for alpha-aminopyridine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.
Topics: Aminopyridines; Animals; Astrocytes; Chondroitin Sulfate Proteoglycans; Cytokines; Disease Models, Animal; Down-Regulation; Extracellular Matrix; Hand Strength; Humans; Huntingtin Protein; Huntington Disease; Inflammation; Mice; Mice, Transgenic; Microglia; Neostriatum; Neurites; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Recognition, Psychology; RNA, Messenger; Synapses; Transcriptome | 2020 |
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Huntington Disease; Inflammation; Male; Neuroprotective Agents; NF-kappa B; Nitrosative Stress; Oxidative Stress; Quinolinic Acid; Rats; Rats, Wistar; Signal Transduction | 2021 |
Lack of effect of 4-aminopyridine on choreic movements.
Topics: 4-Aminopyridine; Aminopyridines; Humans; Huntington Disease; Middle Aged | 1982 |